At least six research teams around the world are currently developing new coronaviruses. Pneumonia outbreaks of new coronavirus infections are spreading at a faster rate, and preventive vaccines are key to fighting a pandemic of major sudden-onset diseases, which is being developed by a growing number of research teams around the world.
On January 28, first financial reporter sprinating from Wuhan Bovo Biotech Co., Ltd. (“Wuhan Bovo”) learned that the company has been working with GeoVax Labs Inc. (OTCQB:GOVX) to jointly develop a new coronavirus 2019-nCoV vaccine.
Both companies are committed to human vaccine development, among which Wuhan Bovo is an indirect subsidiary of Human Fu Pharmaceuticals (SH.600079), and GeoVax is headquartered in Atlanta, USA.
GeoVax will use its MVA-VLP vaccine platform and expertise to design and construct candidate vaccines using coronavirus gene sequences from Wuhan, China. Wuhan Bovo will provide further development support, including testing and production, as well as direct interaction with China’s public health and regulatory authorities.
Wu Ke, founder and chief executive officer of Wuhan Bovo, told First Financial: “This collaboration can take advantage of geoVax Labs’ accelerated progress project to establish an MVA-VLP vaccine platform. “
Also on January 28th, it was also reported that Tongji University Affiliated Oriental Hospital Translational Medicine Platform and Swee (Shanghai) Biotech Co., Ltd. partnered, relying on the “Shanghai Zhangjiang National Independent Innovation Demonstration Zone Stem Cell Strategy Library and Stem Cell Technology Clinical Transformation Platform” task – mRNA synthesis platform results, Rapidly promote the development of a new coronavirus mRNA vaccine. Recently, the project has been urgently completed project filing.
Li Hangwen, part-time PI (project leader) of the Oriental Hospital Translational Medicine Platform and chairman of Microbiology, said that using the relevant platform technology to quickly synthesize mRNAs for a variety of different antigen sequences for the key targets of this new coronavirus, and to prepare preparations through nanolipid (LPP) drug-carrying technology, through in vivo and animal experiments, Screening and validating effective antigens, on this basis will be able to complete large-scale preventive 2019-nCoV vaccine sample production, preparation within 40 days.
On January 24, China’s CDC successfully isolated China’s first new coronavirus virus. The National Pathogen Microbiology Library has released information and electro-mirror photos of the virus (new coronavirus Wuhan strain 01), and important authoritative information such as the detection of primers and probe sequences of the new coronavirus nucleic acid. All of this lays the foundation for vaccine development.
According to the first financial reporter incomplete statistics, at least six research teams around the world are currently developing a new type of coronavirus. As Xu Wenbo, director of the Cdc’s virus institute, said on January 26th, the center began to develop a vaccine for the new coronavirus.
Meanwhile, Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, and Kathleen Paules, an infectious disease specialist at the University of Pennsylvania School of Medicine, wrote in the Journal of the American Medical Association on January 23rd that research on coronaviruses has yielded some results since the outbreak became. This could significantly shorten the time it takes to develop a new coronavirus vaccine, which is expected to begin human clinical trials in three months.
Researchers at the University of Queensland in Australia are using a patented technology called molecular pliers to quickly produce a vaccine against a new coronavirus that could increase the stability of viral proteins. Previously, the team tried to develop the best experimental results using the technology to develop vaccines against MERS coronaviruses, nipa viruses, Ebola viruses and influenza viruses.
At present, the industry’s understanding of the new coronavirus is still very limited, the source of infection has not yet been found, the mechanism of transmission of disease and the risk of mutation is not clear, which poses a challenge to vaccine development.
Ma Xiaowei, director of the National Health and Health Commission, said on January 26th that the new coronavirus is a different strain than SARS and MERS virus, adding a new member to the coronavirus family. From the clinical epidemiological data, the preliminary understanding that the initial virus may be from wild animals to humans, and now gradually began to adapt to human survival, and into the human-to-human period, from the current clinical cases, there are some serious cases, there are some cases of mild illness, the virus has begun to spread in humans. According to recent clinical data, the spread of the virus seems to have increased, the virus’s toxicity and pathogenicity need to be analyzed based on more clinical data.
Once a candidate vaccine is available, the researchers will test it in animals to see if they are safe and produce an immune response.
“The biggest challenge in vaccine development is that there is no suitable animal model for the time being, ” Wu told First Financial. It is not known what animals the virus causes to develop and die, so it is not possible to verify the effectiveness of the vaccine from animal models. “
Chappell, one of the leaders of a new coronavirus vaccine research project at the University of Queensland in Australia, said recently that vaccine development is very difficult, so it is very important for laboratories around the world to develop vaccines simultaneously. “We’re going to race against the virus and fight for the time to develop an effective vaccine for all of humanity,” he said. “